GH Research's GH001 Efficacy Holds Strong Regardless of Prior Treatment Failures, New Data Shows
GHRS sits 75% above its 52-week low of $7.98 on light trading volume (0.1× avg).
Summary
GH Research announced a new analysis of its Phase 2b data for mebufotenin (GH001) in treatment-resistant depression (TRD), demonstrating that the drug's efficacy is independent of the number of prior lifetime antidepressant failures. This finding, published in Psychopharmacology Bulletin alongside the primary Phase 2b results in JAMA Psychiatry, is significant because it contrasts with the typical decline in remission rates seen with increasing prior treatment failures in TRD. While topline Phase 2b results were previously reported in January, this new insight strengthens GH001's profile by suggesting consistent benefit even for patients with extensive treatment histories. This could broaden the drug's potential market and improve its competitive positioning as it advances towards global pivotal trials.
At the time of this announcement, GHRS was trading at $13.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $865.9M. The 52-week trading range was $7.98 to $19.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.